Christopher Cabell - President & Head of R&D at Inhibikase Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
President & Head of R&D
Issuer Symbol
IKT on Nasdaq
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Christopher Cabell since 09 Mar 2025

Holdings reported by Christopher Cabell for Inhibikase Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 676,564 $1,353,128 $2.00 21 Feb 2026 Direct
Stock Option (Right to Buy) 900,117 05 Jan 2026 Direct Common Stock

Transactions reported by Christopher Cabell for Inhibikase Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.